I don't disagree CTMedic. However, there is som
Post# of 154051
(Total Views: 494)
Posted On: 09/15/2020 3:42:31 PM
I don't disagree CTMedic.
However, there is something uncomfortably disingenuous regarding how Dr.NP portrayed the use of those 100M shares to shareholders.
We were told by Dr.NP that the company would probably only use 7-10% of those shares to raise capital -- and that was only if warrant exercises or other positive developments didn't obviate the need to use them at all.
So, shareholder's fears of further dilution were temporarily assuaged. But the next thing we knew 25% of those shares (potentially on top of the 7-10%) are being earmarked for incentives or compensation.
I understand that CytoDyn's planned development path may include staffing-up, and that attracting skilled talent requires incentives. However, in aggregate, we may now be looking at 35% of those 100M shares being used (25M + 10M). That's quite a different story from a disclosure point-of-view.
And let's take this logic one step further. If, for whatever reason, CytoDyn does not gain a COVID approval, at the current SP it will need all of those shares to fund trials and operating expenses until such time that HIV-related revenue is generated.
So, it seems like they're putting the cart before the horse. It would be one thing if they were absolutely positive that we'd be granted an approval or EUA for COVID, but I haven't yet received that memo.
However, there is something uncomfortably disingenuous regarding how Dr.NP portrayed the use of those 100M shares to shareholders.
We were told by Dr.NP that the company would probably only use 7-10% of those shares to raise capital -- and that was only if warrant exercises or other positive developments didn't obviate the need to use them at all.
So, shareholder's fears of further dilution were temporarily assuaged. But the next thing we knew 25% of those shares (potentially on top of the 7-10%) are being earmarked for incentives or compensation.
I understand that CytoDyn's planned development path may include staffing-up, and that attracting skilled talent requires incentives. However, in aggregate, we may now be looking at 35% of those 100M shares being used (25M + 10M). That's quite a different story from a disclosure point-of-view.
And let's take this logic one step further. If, for whatever reason, CytoDyn does not gain a COVID approval, at the current SP it will need all of those shares to fund trials and operating expenses until such time that HIV-related revenue is generated.
So, it seems like they're putting the cart before the horse. It would be one thing if they were absolutely positive that we'd be granted an approval or EUA for COVID, but I haven't yet received that memo.
(7)
(0)